Organogenesis Holdings Inc.
A regenerative-medicine company that grows living skin and tissue grafts to help wounds heal. Its best-known product, Apligraf, was the first living cell-based skin substitute approved by the U.S. Food and Drug Administration, and its PuraPly line treats chronic wounds like diabetic ulcers. Founded in 1985 in Cambridge, Massachusetts, the company's name reflects its mission of growing organs and tissues in the lab.
Sold 215.9K
Sold 215.9K
Bought 358.5K · Sold 522.8K
Granted 2.65M · Sold 380.0K
Granted 572.8K
Granted 358.3K · Bought 252.3K
Granted 410.4K
Granted 369.5K
Granted 149.4K · Bought 5.0K
Granted 78.2K
Granted 149.4K
Granted 149.4K
Granted 149.4K
Granted 149.4K
Granted 97.6K
Granted 149.4K · Bought 10.0K · Sold 25.0K
Granted 98.4K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Ades Alan A. +9 co-filersDirector, 10% owner, 10% owner · 6 transactions | — | 153.26Mas of Jan 2025 | — | — | — |
| Ades Alan A. +5 co-filersDirector, 10% owner, 10% owner · 6 transactions | — | 153.26Mas of Jan 2025 | — | — | — |
| Ades Alan A. +9 co-filersDirector, 10% owner, 10% owner · 2 transactions | -0.4% | 59.01Mas of Jan 2024 | — | — | 215.9K |
| Erani Albert +3 co-filers10% owner · 2 transactions | -0.4% | 59.01Mas of Jan 2024 | — | — | 215.9K |
| Ades Alan A. +7 co-filersDirector, 10% owner, 10% owner · 5 transactions | — | 54.14Mas of Nov 2024 | — | — | — |
| Ades Alan A. +9 co-filersDirector, 10% owner, 10% owner · 6 transactions | — | 51.09Mas of Nov 2024 | — | — | — |
| Erani Dennis +3 co-filers10% owner · 1 transaction | — | 51.09Mas of Nov 2024 | — | — | — |
| Nussdorf Glenn HDirector · 8 transactions | — | 22.74M | — | 358.5K | 522.8K |
| Gillheeney Gary S.President and CEO, Director · 24 transactions | +144.5% | 4.32M | 2.65M | — | 380.0K |
| Bilbo PatrickChief Operating Officer · 17 transactions | +124.6% | 1.13M | 572.8K | — | — |
| Freedman LoriChief Admin. and Legal Officer · 19 transactions | +197.6% | 1.02M | 358.3K | 252.3K | — |
| Grow BrianChief Commercial Officer · 19 transactions | +144.9% | 911.6K | 410.4K | — | — |
| Francisco DavidChief Financial Officer · 15 transactions | +155.5% | 746.0K | 369.5K | — | — |
| Leibowitz Arthur SDirector · 4 transactions | +113.1% | 291.0K | 149.4K | 5.0K | — |
| Cavorsi RobertVice President, Strategy · 14 transactions | — | 275.5K | 78.2K | — | — |
| Duraibabu PrathyushaDirector · 3 transactions | +153.1% | 247.0K | 149.4K | — | — |
| Giacomin Jon LDirector · 3 transactions | +163.1% | 241.0K | 149.4K | — | — |
| Korfin Michele IleneDirector · 3 transactions | +166.7% | 239.1K | 149.4K | — | — |
| Quintero GilbertoDirector · 3 transactions | +166.7% | 239.1K | 149.4K | — | — |
| Montecalvo Antonio S.Vice President, Health Policy · 16 transactions | +68% | 230.0K | 97.6K | — | — |
| Driscoll Michael JosephDirector · 5 transactions | +147.3% | 225.7K | 149.4K | 10.0K | 25.0K |
| Lustig GarrettDirector · 2 transactions | — | 125.7K | 98.4K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 3 years: -733.8K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.